The journey from melanocytes to melanoma
PP Centeno, V Pavet, R Marais - Nature Reviews Cancer, 2023 - nature.com
Over the past decade, melanoma has led the field in new cancer treatments, with impressive
gains in on-treatment survival but more modest improvements in overall survival. Melanoma …
gains in on-treatment survival but more modest improvements in overall survival. Melanoma …
Targeting senescent cells for a healthier aging: challenges and opportunities
S Song, T Tchkonia, J Jiang, JL Kirkland… - Advanced …, 2020 - Wiley Online Library
Aging is a physiological decline in both structural homeostasis and functional integrity,
progressively affecting organismal health. A major hallmark of aging is the accumulation of …
progressively affecting organismal health. A major hallmark of aging is the accumulation of …
SPRY4 regulates trophoblast proliferation and apoptosis via regulating IFN‐γ‐induced STAT1 expression and activation in recurrent miscarriage
S Qin, Y Zhang, J Zhang, F Tian, L Sun… - American Journal of …, 2020 - Wiley Online Library
Problem The dysregulation of trophoblast functions is one of the leading causes of recurrent
miscarriage (RM), which frustrates 1%‐5% of couples of childbearing ages. Sprouty 4 …
miscarriage (RM), which frustrates 1%‐5% of couples of childbearing ages. Sprouty 4 …
Mefloquine induces ER stress and apoptosis in BRAFi‐resistant A375‐BRAFV600E/NRASQ61K malignant melanoma cells targeting intracranial tumors in a …
J Jandova, SL Park, MJ Corenblum… - Molecular …, 2022 - Wiley Online Library
Molecularly targeted therapeutics have revolutionized the treatment of BRAFV600E‐driven
malignant melanoma, but the rapid development of resistance to BRAF kinase inhibitors …
malignant melanoma, but the rapid development of resistance to BRAF kinase inhibitors …
Immune-related risk score: An immune-cell-pair-based prognostic model for cutaneous melanoma
M Li, X Long, W Bu, G Zhang, G Deng, Y Liu… - Frontiers in …, 2023 - frontiersin.org
Background Melanoma is among the most malignant immunologic tumor types and is
associated with high mortality. However, a considerable number of melanoma patients …
associated with high mortality. However, a considerable number of melanoma patients …
SPRY4 inhibits and sensitizes the primary KIT mutants in gastrointestinal stromal tumors (GISTs) to imatinib
S Li, S Zhao, N Liang, S Zhang, L Zhang, L Zhou, A Liu… - Gastric Cancer, 2023 - Springer
Background KIT is frequently mutated in gastrointestinal stromal tumors (GISTs), and the
treatment of GISTs largely relies on targeting KIT currently. In this study, we aimed to …
treatment of GISTs largely relies on targeting KIT currently. In this study, we aimed to …
[HTML][HTML] Vemurafenib Drives Epithelial-to-Mesenchymal Transition Gene Expression in BRAF Inhibitor‒Resistant BRAFV600E/NRASQ61K Melanoma Enhancing …
J Jandova, GT Wondrak - Journal of Investigative Dermatology, 2022 - Elsevier
BRAF inhibitor (BRAFi) resistance compromises long-term survivorship of patients with
malignant melanoma, and mutant NRAS is a major mediator of BRAFi resistance. In this …
malignant melanoma, and mutant NRAS is a major mediator of BRAFi resistance. In this …
Circulating miRNAs in small extracellular vesicles secreted by a human melanoma xenograft in mouse brains
L Guglielmi, M Nardella, C Musa, I Cifola, M Porru… - Cancers, 2020 - mdpi.com
The identification of liquid biomarkers remains a major challenge to improve the diagnosis of
melanoma patients with brain metastases. Circulating miRNAs packaged into tumor …
melanoma patients with brain metastases. Circulating miRNAs packaged into tumor …
Oncogenetic network estimation with disjunctive Bayesian networks
PB Nicol, KR Coombes, C Deaver… - Computational and …, 2021 - Wiley Online Library
Motivation: Cancer is the process of accumulating genetic alterations that confer selective
advantages to tumor cells. The order in which aberrations occur is not arbitrary, and inferring …
advantages to tumor cells. The order in which aberrations occur is not arbitrary, and inferring …
Vemurafenib drives EMT gene expression in BRAFi-resistant BRAFV600E/NRASQ61K melanoma enhancing tumor growth and metastasis in a bioluminescent murine …
J Jandova, GT Wondrak - The Journal of investigative …, 2021 - pmc.ncbi.nlm.nih.gov
BRAF-inhibitor (BRAFi)-resistance compromises long term survivorship of malignant
melanoma patients, and mutant NRAS is a major mediator of BRAFi-resistance. Here …
melanoma patients, and mutant NRAS is a major mediator of BRAFi-resistance. Here …